The Second Round of a Population-Based Seroprevalence Study of Anti–SARS-CoV-2 Antibodies and COVID-19 Vaccination Assessment in the Republika Srpska, Bosnia and Herzegovina

IF 4.3 4区 医学 Q1 INFECTIOUS DISEASES
Jela Aćimović, Biljana Mijović, Srđan Mašić, Miroslav Petković, Dragana Puhalo Sladoje, Darija Knežević, Jelena Đaković Dević, Dragan Spaić, Jelena Vladičić-Mašić, Dejan Bokonjić, Mirza Palo, Aisling Vaughan, Richard Pebody, Anthony Nardone, Ranko Škrbić
{"title":"The Second Round of a Population-Based Seroprevalence Study of Anti–SARS-CoV-2 Antibodies and COVID-19 Vaccination Assessment in the Republika Srpska, Bosnia and Herzegovina","authors":"Jela Aćimović,&nbsp;Biljana Mijović,&nbsp;Srđan Mašić,&nbsp;Miroslav Petković,&nbsp;Dragana Puhalo Sladoje,&nbsp;Darija Knežević,&nbsp;Jelena Đaković Dević,&nbsp;Dragan Spaić,&nbsp;Jelena Vladičić-Mašić,&nbsp;Dejan Bokonjić,&nbsp;Mirza Palo,&nbsp;Aisling Vaughan,&nbsp;Richard Pebody,&nbsp;Anthony Nardone,&nbsp;Ranko Škrbić","doi":"10.1111/irv.70053","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Introduction</h3>\n \n <p>The aim of the study was to assess the seroprevalence of SARS-CoV-2 in the Republika Srpska, Bosnia and Herzegovina, after five waves of COVID-19 and 1 year after introduction of vaccination to better understand the true extent of the COVID-19 pandemic in the population of the Republika Srpska and role of vaccination in achieving herd immunity.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>The population-based study was conducted from December 2021 to February 2022 in a group of 4463 individuals in the Republika Srpska. Total anti–SARS-CoV-2 antibodies were determined in serum specimens using the Wantai total antibody ELISA assay. Quantitative analysis, using Kantaro IgG assays, was performed in subsamples (1273 specimens) to asses and compare levels of IgG among vaccinated, recovered and participants with hybrid immunity. To adjust for age and gender distribution in sample, poststratification method is applied.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The overall cumulative seroprevalence was 94.6% (95% CI = 93.9–95.3). Significantly higher seroprevalence rates were observed among vaccinated 97.8% (95% CI = 97.3–98.4) comparing to unvaccinated participants (89.5%, 95% CI = 88.0–91.0). Seroprevalence increases with the number of received doses. Among various professions, the highest seroprevalence was found in the service industry (98.1%), education (98.0%) and healthcare (96.9%). We found that 2.2% of vaccinated and 3.6% of participants with SARS-CoV-2 positivity during 2021 had no detectable IgG antibodies. Both seroprevalence (98.6%) and antibody titres (1094.4 AU/mL) were significantly higher among people with hybrid immunity.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Our findings reveal a 2.3-fold increase in seroprevalence of SARS-CoV-2 antibodies due to infection and vaccination, comparing to the first study performed 1 year earlier. This study provides better understanding of the SARS-CoV-2 transmission and highlights the important role of the vaccination in achieving the population immunity. Periodically conducted population-based seroprevalence studies are important to understand temporal trends and assess surveillance system performance and public compliance with vaccination policies.</p>\n </section>\n </div>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"19 1","pages":""},"PeriodicalIF":4.3000,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11739130/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Influenza and Other Respiratory Viruses","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/irv.70053","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction

The aim of the study was to assess the seroprevalence of SARS-CoV-2 in the Republika Srpska, Bosnia and Herzegovina, after five waves of COVID-19 and 1 year after introduction of vaccination to better understand the true extent of the COVID-19 pandemic in the population of the Republika Srpska and role of vaccination in achieving herd immunity.

Methods

The population-based study was conducted from December 2021 to February 2022 in a group of 4463 individuals in the Republika Srpska. Total anti–SARS-CoV-2 antibodies were determined in serum specimens using the Wantai total antibody ELISA assay. Quantitative analysis, using Kantaro IgG assays, was performed in subsamples (1273 specimens) to asses and compare levels of IgG among vaccinated, recovered and participants with hybrid immunity. To adjust for age and gender distribution in sample, poststratification method is applied.

Results

The overall cumulative seroprevalence was 94.6% (95% CI = 93.9–95.3). Significantly higher seroprevalence rates were observed among vaccinated 97.8% (95% CI = 97.3–98.4) comparing to unvaccinated participants (89.5%, 95% CI = 88.0–91.0). Seroprevalence increases with the number of received doses. Among various professions, the highest seroprevalence was found in the service industry (98.1%), education (98.0%) and healthcare (96.9%). We found that 2.2% of vaccinated and 3.6% of participants with SARS-CoV-2 positivity during 2021 had no detectable IgG antibodies. Both seroprevalence (98.6%) and antibody titres (1094.4 AU/mL) were significantly higher among people with hybrid immunity.

Conclusion

Our findings reveal a 2.3-fold increase in seroprevalence of SARS-CoV-2 antibodies due to infection and vaccination, comparing to the first study performed 1 year earlier. This study provides better understanding of the SARS-CoV-2 transmission and highlights the important role of the vaccination in achieving the population immunity. Periodically conducted population-based seroprevalence studies are important to understand temporal trends and assess surveillance system performance and public compliance with vaccination policies.

Abstract Image

波斯尼亚和黑塞哥维那塞族共和国第二轮基于人群的抗sars - cov -2抗体血清阳性率研究和COVID-19疫苗接种评估
本研究的目的是评估波斯尼亚和黑塞哥维那斯普斯卡共和国在经历五波COVID-19和引入疫苗接种一年后的SARS-CoV-2血清患病率,以更好地了解斯普斯卡共和国人口中COVID-19大流行的真实程度以及疫苗接种在实现群体免疫中的作用。方法:这项基于人群的研究于2021年12月至2022年2月在斯普斯卡共和国的4463名个体中进行。采用万泰总抗体ELISA法测定血清标本中总抗sars - cov -2抗体。使用Kantaro IgG测定法对亚样本(1273个样本)进行定量分析,以评估和比较接种疫苗者、康复者和混合免疫者的IgG水平。为了调整样本的年龄和性别分布,采用了后分层方法。结果:总累积血清阳性率为94.6% (95% CI = 93.9 ~ 95.3)。与未接种疫苗的参与者(89.5%,95% CI = 88.0-91.0)相比,接种疫苗的参与者(97.8%,95% CI = 97.3-98.4)的血清患病率显著高于未接种疫苗的参与者(89.5%,95% CI = 88.0-91.0)。血清阳性率随着接受剂量的增加而增加。在不同的职业中,血清阳性率最高的是服务业(98.1%)、教育(98.0%)和医疗保健(96.9%)。我们发现,在2021年期间,2.2%的疫苗接种者和3.6%的SARS-CoV-2阳性参与者没有检测到IgG抗体。混合免疫人群血清阳性率(98.6%)和抗体滴度(1094.4 AU/mL)均显著高于混合免疫人群。结论:我们的研究结果显示,与一年前进行的第一次研究相比,由于感染和接种疫苗,SARS-CoV-2抗体的血清阳性率增加了2.3倍。本研究对SARS-CoV-2的传播提供了更好的认识,并强调了疫苗接种在实现人群免疫中的重要作用。定期开展以人群为基础的血清流行率研究对于了解时间趋势和评估监测系统的表现以及公众对疫苗接种政策的依从性非常重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
7.20
自引率
4.50%
发文量
120
审稿时长
6-12 weeks
期刊介绍: Influenza and Other Respiratory Viruses is the official journal of the International Society of Influenza and Other Respiratory Virus Diseases - an independent scientific professional society - dedicated to promoting the prevention, detection, treatment, and control of influenza and other respiratory virus diseases. Influenza and Other Respiratory Viruses is an Open Access journal. Copyright on any research article published by Influenza and Other Respiratory Viruses is retained by the author(s). Authors grant Wiley a license to publish the article and identify itself as the original publisher. Authors also grant any third party the right to use the article freely as long as its integrity is maintained and its original authors, citation details and publisher are identified.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信